Morgan Stanley Maintains Equal-Weight on Quest Diagnostics, Lowers Price Target to $159
Morgan Stanley maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and lowers the price target from $165 to $159.
Keybanc Maintains Overweight on Quest Diagnostics, Raises Price Target to $170
Keybanc maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $168 to $170.
‘Senate votes to repeal key Biden administration vaccine and testing policy’ -Earlier Washington Post Report
https://www.washingtonpost.com/us-policy/2021/12/08/republicans-vaccine-congress-coronavirus/
White House Chief Of Staff Ronald Klain Says President Biden Will Announce Today ‘FREE and RELIABLE’ COVID At Home Tests
https://twitter.com/WHCOS/status/1466404937525567496?s=20
Wall Street Crime And Punishment: The Blood On Elizabeth Holmes’ Fingers
Does crime pay?
Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition and greed take them in the wrong direction.
What 5 Analyst Ratings Have To Say About Quest Diagnostics
Within the last quarter, Quest Diagnostics (NYSE:DGX) has observed the following analyst ratings:
Wells Fargo Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $150
Wells Fargo analyst Dan Leonard maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from $140 to $150.
Quest Raises FY21 Outlook Again On Strong COVID-19 Volumes In Q3
Quest Diagnostics Incorporated (NYSE:DGX) has posted a better-than-expected Q3 adjusted EPS of $3.96, down 7.9% Y/Y, beating the consensus estimate…